Mankind Pharma announced that its credit ratings have been partially reaffirmed and withdrawn. Ratings for ₹400 crore and ₹4,600 crore Non-Convertible Debentures, along with ₹1,500 crore Commercial Paper, have been reaffirmed. However, the rating for Total Bank Loan Facilities Rated at ₹1,250 crore has been withdrawn.
Credit Rating Update
Mankind Pharma has announced updates regarding its credit ratings following a review by CRISIL Ratings Limited, as of October 29, 2025. The announcement details both reaffirmations and withdrawals of credit ratings for various financial instruments.
Reaffirmed Ratings
The credit ratings for the following instruments have been reaffirmed:
- Non-Convertible Debentures: ₹400 crore (Crisil AA+/Stable)
- Non-Convertible Debentures: ₹4,600 crore (Crisil AA+/Stable)
- Commercial Paper: ₹1,500 crore (Crisil A1+)
The ₹1,500 crore Commercial Paper amount reflects a reduction from the previous ₹5,000 crore.
Withdrawn Rating
The credit rating for the following instrument has been withdrawn:
- Total Bank Loan Facilities Rated: ₹1,250 crore (Crisil AA+/Stable)
Source: BSE